Trial of Psilocybin versus Escitalopram for Depression
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Psilocybin may have antidepressant properties, but direct comparisons between psilocybin and established treatments for depression are lacking. METHODS: In a phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder, we compared psilocybin with escitalopram, a selective serotonin-reuptake inhibitor, over a 6-week period. Patients were assigned in a 1:1 ratio to receive two separate doses of 25 mg of psilocybin 3 weeks apart plus 6 weeks of daily placebo (psilocybin group) or two separate doses of 1 mg of psilocybin 3 weeks apart plus 6 weeks of daily oral escitalopram (escitalopram group); all the patients received psychological support. The primary outcome was the change from baseline in the score on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16; scores range from 0 to 27, with higher scores indicating greater depression) at week 6. There were 16 secondary outcomes, including QIDS-SR-16 response (defined as a reduction in score of >50%) and QIDS-SR-16 remission (defined as a score of ≤5) at week 6. RESULTS: A total of 59 patients were enrolled; 30 were assigned to the psilocybin group and 29 to the escitalopram group. The mean scores on the QIDS-SR-16 at baseline were 14.5 in the psilocybin group and 16.4 in the escitalopram group. The mean (±SE) changes in the scores from baseline to week 6 were -8.0±1.0 points in the psilocybin group and -6.0±1.0 in the escitalopram group, for a between-group difference of 2.0 points (95% confidence interval [CI], -5.0 to 0.9) (P = 0.17). A QIDS-SR-16 response occurred in 70% of the patients in the psilocybin group and in 48% of those in the escitalopram group, for a between-group difference of 22 percentage points (95% CI, -3 to 48); QIDS-SR-16 remission occurred in 57% and 28%, respectively, for a between-group difference of 28 percentage points (95% CI, 2 to 54). Other secondary outcomes generally favored psilocybin over escitalopram, but the analyses were not corrected for multiple comparisons. The incidence of adverse events was similar in the trial groups. CONCLUSIONS: On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are required to compare psilocybin with established antidepressants. (Funded by the Alexander Mosley Charitable Trust and Imperial College London's Centre for Psychedelic Research; ClinicalTrials.gov number, NCT03429075.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In two recent psilocybin clinical trials, ~95% of all volunteers were eliminated on the basis of exclusion criteria”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [8]
In the citing paper
“Amelioration of symptomatic depression in pilot studies of major depressive disorder, including those that compared psilocybin with escitalopram 8,9 and that investigated its use in treatment-resistant depression, 10 has suggested therapeutic potential for this agent.”
From Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression (2022) · cites this paper as [9]
In the citing paper
“Studies have used inactive placebos (e.g., [17, 35]), active placebos whose effects considerably differ from the acute effects of serotonergic psychedelics (e.g., [15, 36, 37]), or doses of psilocybin presumably too low to maintain blinding (e.g., [38, 39])”
In the citing paper
“Contemporary clinical studies have involved one to three dosing sessions (e.g., [38, 39, 117])”
In the citing paper
“Research on MDD, anxiety and depressive symptoms associated with life-threatening cancer, and TRD showed the most robust evidence, supported by a non-randomized study 72 and several RCTs. 26,31-33,60,73-77”
From The revival of psilocybin between scientific excitement, evidence of efficacy, and real-world challenges (2024) · cites this paper as [26]
15 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Self-citationEffects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Cited by
Items 101–200 of 1,001
Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample
Nygart, V. A., Pommerencke, L. M., Haijen, E., Kettner, H., Kaelen, M., Mortensen, E. L., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221101061 · Cited by 73
“Notably, improvements in symptom severity have been observed several months after just one or two isolated doses of the drug (Carhart-Harris et al., 2017, 2021a; Davis et al., 2021a; Gasser et al., 2014; Griffiths et al., 2016; Grob et al., 2011).”
BackgroundResultSelf-citationDrug–drug interactions involving classic psychedelics: A systematic review
Halman, A., Kong, G., Sarris, J. J., & Perkins, D. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231211219 · Cited by 80
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
Spriggs, M. J., Douglass, H. M., Park, R. J., Read, T., Danby, J. L., de Magalhães, F. J. C., Alderton, K. L., Williams, T. M., Blemings, A., Lafrance, A., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735523 · Cited by 75
“This study is funded by the funders of Imperial College London’s Centre for Psychedelic Research (https://www.imperial.ac.uk/ psychedelic-research-centre/funding-partners/), with specific support from The Nikean Foundation.”
BackgroundResultInfluentialSelf-citationThe therapeutic potential of psilocybin: a systematic review
van Amsterdam, J., & van den Brink, W. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047929 · Cited by 74
“Table 1 shows that the positive outcomes generally occurred very quickly and clinical improvements after the last psilocybin session lasted up to 4–6 weeks [24,25], 3 months [18,26], 6 months [27–30], or even 12 months [31].”
Transformative experience and informed consent to psychedelic-assisted psychotherapy
Jacobs, E. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1108333 · Cited by 79
“Suppose that the results of the only published study directly comparing PAP to treatment as usual (Carhart-Harris et al., 2021)—i.”
BackgroundResultThe polypharmacology of psychedelics reveals multiple targets for potential therapeutics
Jain, M. K., Gumpper, R. H., Slocum, S. T., Schmitz, G. P., Madsen, J. S., Tummino, T. A., Suomivuori, C., Huang, X.-P., Shub, L., DiBerto, J. F., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.06.012 · Cited by 89
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73
“In the psilocybin group 21 of 30 participants responded and 17 of 30 participants remitted (response defined as a reduction in QIDS-SR-16 score of >50% and remission defined as a score of≤5)whereas in the escitalopram group 14 of 29 participants responded and 8 of 29 participants remitted, however, the differences in…”
The varieties of psychedelic law
Marks, M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109399 · Cited by 73
Ethical and Practical Considerations for the Use of Psychedelics in Psychiatry
Barber, G., & Dike, C. C. (2023) · Psychiatric Services · doi:10.1176/appi.ps.20220525 · Cited by 82
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 74
Novel ethical and policy issues in psychiatric uses of psychedelic substances
Smith, W. R., & Appelbaum, P. S. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109165 · Cited by 65
A unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 78
“We hope this manuscript paves the way for more research on KAP, particularly stimulating RCTs which can generate the approval of ketamine as a treatment for TRD and other disorders.”
InfluentialPharmacokinetics of N,N-dimethyltryptamine in Humans
Good, M., Joel, Z., Benway, T. A., Routledge, C. A., Timmermann, C., Erritzøe, D., Weaver, R., Allen, G., Hughes, C., Topping, H., et al. (2023) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-023-00822-y · Cited by 77
“Sensation of pain/reaction at administration sitea 1 [1] 2 [2] 1 [1] 2 [2] 1 [1]”
BackgroundAlsayednasser, B., Widnall, E., O’Mahen, H., Wright, K. A., Warren, F. C., Ladwa, A., Khazanov, G. K., Byford, S., Kuyken, W., Watkins, E. R., et al. (2022) · Behaviour Research and Therapy · doi:10.1016/j.brat.2022.104185 · Cited by 74
Therapeutic mechanisms of psychedelics and entactogens
Heifets, B. D., & Olson, D. E. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01666-5 · Cited by 79
“However, studies of healthy volunteers and secondary analyses of therapeutic trials suggest that for psychedelics and entactogens, respectively, similar acute and long-term behavioral effects occur regardless of the initial disease state [26, 83, 147, 209, 210].”
BackgroundInfluentialPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“Similarly, one week after psilocybin therapy, glutamate and N-acetylaspartate concentrations were decreased in the Anterior Cingulate Cortex (ACC) in an open-label study of 24 patients with MDD (83).”
BackgroundInfluentialBarnett, B. S., Beaussant, Y., King, F., & Doblin, R. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1957183 · Cited by 71
“Psilocybin has shown promise in treating anxiety and depression (Agin-Liebes et al. 2020; Carhart-Harris et al. 2021), and Phase 2 trials are currently investigating its treatment potential for both major depressive disorder (Business Wire 2019) and treatmentresistant major depressive disorder…”
BackgroundRosenblat, J. D., Husain, M. I., Lee, Y. L., McIntyre, R. S., Mansur, R. B., Castle, D. J., Offman, H., Parikh, S. V., Frey, B. N., Schaffer, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221111371 · Cited by 76
“The same research group completed a phase 2, double-blind RCT involving patients with long-standing, moderate-to-severe MDD, comparing psilocybin-assisted psychotherapy with escitalopram, over a 6-week period (n = 59).(67) Participants were randomized to receive two separate doses of 25 mg of psilocybin with psychothe…”
BackgroundThe Emerging Field of Psychedelic Psychotherapy
Barber, G., & Aaronson, S. T. (2022) · Current Psychiatry Reports · doi:10.1007/s11920-022-01363-y · Cited by 74
Zeifman, R. J., Wagner, A. C., Monson, C. M., & Carhart-Harris, R. L. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.04.105 · Cited by 60
Self-citationLuppi, A. I., Hansen, J. Y., Ram, A., Carhart-Harris, R. L., Roseman, L., Timmermann, C., Golkowski, D., Ranft, A., Ilg, R., Jordan, D., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf8332 · Cited by 75
Self-citationCardiovascular safety of psychedelic medicine: current status and future directions
Wsół, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00539-4 · Cited by 76
Erritzøe, D., Barba, T., Greenway, K. T., Murphy, R., Martell, J., Giribaldi, B., Timmermann, C., Murphy-Beiner, A., Baker-Jones, M., Nutt, D. J., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102799 · Cited by 73
Self-citationAttenuation of psilocybin mushroom effects during and after SSRI/SNRI antidepressant use
Gukasyan, N., Griffiths, R. R., Yaden, D. B., Antoine, D. G., & Nayak, S. M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231179910 · Cited by 67
Understanding the effects of serotonin in the brain through its role in the gastrointestinal tract
Shine, J. M., O’Callaghan, C., Walpola, I. C., Wainstein, G., Taylor, N. L., Aru, J., Huebner, B., & John, Y. J. (2022) · Brain · doi:10.1093/brain/awac256 · Cited by 73
“135,136 137 – 140 The augmentation of 5-HT 2A Rs would contribute to a fl ux state — consistent with the idea that ser-otonergictherapyhasapermissivefunction:shiftingthesystemto-wards a set of possible options, 141 allowing individuals to reappraise situations that they had otherwise responded to…”
Lutkajtis, A., & Evans, J. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00232 · Cited by 70
“In particular, studies suggest that psychedelics may be an effective treatment for a variety of clinical issues, including treatment-resistant depression (Carhart-Harris et al., 2021), cancer-related distress (Griffiths et al.”
BackgroundSafety and risk assessment of psychedelic psychotherapy: A meta-analysis and systematic review
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.115880 · Cited by 74
Sloshower, J., Zeifman, R. J., Guss, J., Krause, R., Safi-Aghdam, H., Pathania, S., Pittman, B., & D’Souza, D. C. (2024) · Scientific Reports · doi:10.1038/s41598-024-58318-x · Cited by 65
“In a sample with MDD, a recent randomized controlled trial found that, relative to escitalopram, psilocybin-assisted therapy led to greater increases in experiential acceptance 5 .”
ResultSmausz, R., Neill, J. C., & Gigg, J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221092508 · Cited by 70
“In fact, recent Phase-2 clinical trials comparing the antidepressant efficacy of two 25 mg oral doses of psilocybin versus escitalopram, a selective serotonin reuptake inhibitor presently used for treating MDD, found that both compounds successfully reduced self-reporting scores on the 16-item Quick Inventory of Depre…”
BackgroundMethodPsychedelic Commercialization: A Wide-Spanning Overview of the Emerging Psychedelic Industry
Aday, J. S., Barnett, B. S., Grossman, D., Murnane, K. S., Nichols, C. D., & Hendricks, P. S. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0013 · Cited by 68
“…support surrounding the administration of psychedelic drugs, positive clinical and safety outcomes have been documented in patients with depression, 9 anxiety, 10 substance use disorders, 11 end-of-life distress, 12 obsessive-compulsive disorder, 13 and posttraumatic-stress disorder (PTSD).”
Psychedelic-induced mystical experiences: An interdisciplinary discussion and critique
Mosurinjohn, S. C., Roseman, L., & Girn, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1077311 · Cited by 74
“Making these comparisons can do two crucial things: (1) give us clues about the specificity of what psychedelic molecules are doing; and (2) build more robust models of what psychedelic experiences are doing.”
BackgroundNoorani, T. N., Bedi, G., & Muthukumaraswamy, S. D. (2023) · Psychological Medicine · doi:10.1017/s0033291723001289 · Cited by 69
“In the past two years alone, six RCTs have been published, between them including 514 participants (Bogenschutz et al., 2022; Carhart-Harris et al., 2021; Davis et al., 2021; Goodwin et al., 2022; Mitchell et al., 2021; Schindler et al., 2021).”
BackgroundRisk of bias in randomized clinical trials on psychedelic medicine: A systematic review
Hovmand, O. R., Poulsen, E. D., Arnfred, S., & Storebø, O. J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231180276 · Cited by 72
“(d) Four trials (Gasser et al., 2014; Grob et al., 2011; Griffiths et al., 2016; Ross et al., 2016) utilized a randomized crossover or randomized within-subjects design.”
InfluentialRieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., von Rotz, R., Nordt, C., Visentini, M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103149 · Cited by 69
Group VR experiences can produce ego attenuation and connectedness comparable to psychedelics
Glowacki, D. R., Williams, R. R., Wonnacott, M., Maynard, O., Freire, R., Pike, J. E., & Chatziapostolou, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-12637-z · Cited by 74
“In this respect, psychedelic drugs (YDs) have emerged as a particularly promising way of producing subjective phenomenology similar to non-drug MTEs 11 , and are associated with lasting therapeutic benefit in addressing depression, addiction, and end-of-life-anxiety 4,13–16 .”
BackgroundEffects of psilocybin versus escitalopram on rumination and thought suppression in depression
Barba, T., Buehler, S., Kettner, H., Radu, C., Cunha, B. G., Nutt, D. J., Erritzoe, D., Roseman, L., & Carhart-Harris, R. (2022) · BJPsych Open · doi:10.1192/bjo.2022.565 · Cited by 57
Self-citationSolmi, M., Chen, C., Dauré, C., Buot, A., Ljuslin, M., Verroust, V., Mallet, L., Khazaal, Y., Rothen, S., Thorens, G., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.004 · Cited by 66
The economics of psychedelic-assisted therapies: A research agenda
Marseille, E. A., Bertozzi, S., & Kahn, J. G. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1025726 · Cited by 68
“A double-blind randomized controlled trial (RCT) published in 2021 comparing psilocybin with escitalopram, a selective serotonin-reuptake inhibitor (SSRI), for patients with chronic major depression found no significant difference in depression scores, though psilocybin was superior on secondary measures of depression…”
BackgroundHolze, F., Singh, N., Liechti, M. E., & D’Souza, D. C. (2024) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2024.01.007 · Cited by 78
Shahar, O., Botvinnik, A., Esh-Zuntz, N., Brownstien, M., Wolf, R., Lotan, A., Wolf, G., Lerer, B., & Lifschytz, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214148 · Cited by 65
“In the controlled trial of Carhart-Harris (Carhart-Harris et al., 2021) in which psilocybin was shown to be equivalent in efficacy to the SSRI, escitalopram, psychedelic doses of psilocybin were used.”
BackgroundMethodInfluentialAyahuasca: A review of historical, pharmacological, and therapeutic aspects
Ruffell, S., Crosland‐Wood, M., Palmer, R., Netzband, N., Tsang, W., Weiss, B., Gandy, S., Cowley‐Court, T., Halman, A., McHerron, D., et al. (2023) · Psychiatry and Clinical Neurosciences Reports · doi:10.1002/pcn5.146 · Cited by 76
“37 38 – 46 However, anthropological and qualitative articles emphasize the significance of B. caapi .”
BackgroundSabé, M., Sulstarova, A., Glangetas, A., Pieri, M. D., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L. E., Seragnoli, F., Thorens, G., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02800-5 · Cited by 72
“We detail these studies in the supplements (Supplementary Information 3).”
Two Models of Legalization of Psychedelic Substances: Reasons for Concern
Smith, W., & Appelbaum, P. S. (2021) · JAMA · doi:10.1001/jama.2021.12481 · Cited by 73
Psychiatric risks for worsened mental health after psychedelic use
Marrocu, A., Kettner, H., Weiss, B., Zeifman, R. J., Erritzoe, D., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241232548 · Cited by 60
Self-citationThe challenges ahead for psychedelic ‘medicine’
Muthukumaraswamy, S. D., Forsyth, A., & Sumner, R. L. (2022) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221081763 · Cited by 62
“While it is tempting to think about psychedelic drug trials within the framework of standard drug trials, in the most prevalent models being developed (Carhart-Harris et al., 2021; Mitchell et al., 2021), psychedelic drug interventions are usually coupled with some form of psychotherapy.”
BackgroundReview of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 67
Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice
Jaster, A. M., Younkin, J., Cuddy, T., Revenga, M. D. L. F., Poklis, J. L., Dozmorov, M. G., & González‐Maeso, J. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136836 · Cited by 66
Chen, T., Cheng, L., Ma, J., Yuan, J., Pi, C., Xiong, L., Chen, J., Liu, H., Tang, J., Zhong, Y., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106837 · Cited by 52
Wolff, M., Mertens, L. J., Walter, M., Enge, S., & Evens, R. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211073758 · Cited by 58
“Converging evidence from psychometric tests (Carhart-Harris et al., 2021; Griffiths et al., 2016), neuroimaging studies (Mertens et al.”
BackgroundBreeksema, J. J., Niemeijer, A., Krediet, E., Karsten, T., Kamphuis, J., Vermetten, E., van den Brink, W., & Schoevers, R. (2024) · Scientific Reports · doi:10.1038/s41598-024-53188-9 · Cited by 58
“A post hoc analysis of a one recent trial 12 indicated that patients who received psilocybin without discontinuation of their antidepressants had better outcomes than those who did 53 .”
MethodReckweg, J., Mason, N. L., van Leeuwen, C., Toennes, S. W., Terwey, T. H., & Ramaekers, J. G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.760671 · Cited by 58
Associations between lifetime classic psychedelic use and cardiometabolic diseases
Simonsson, O., Osika, W., Carhart-Harris, R. L., & Hendricks, P. S. (2021) · Scientific Reports · doi:10.1038/s41598-021-93787-4 · Cited by 59
Self-citationDevenot, N., Conner, T., & Doyle, R. (2022) · Anthropology of Consciousness · doi:10.1111/anoc.12154 · Cited by 68
Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes
Matzopoulos, R., Morlock, R., Morlock, A., Lerer, B., & Lerer, L. B. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780696 · Cited by 65
5-MeO-DMT modifies innate behaviors and promotes structural neural plasticity in mice
Jefferson, S. J., Gregg, I., Dibbs, M., Liao, C., Wu, H., Davoudian, P. A., Woodburn, S. C., Wehrle, P. H., Sprouse, J. S., Sherwood, A. M., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01572-w · Cited by 65
“Specifically, psilocybin-assisted psychotherapy has been shown to be efficacious for major depression and treatment-resistant depression in Phase 2 clinical trials [6, 7].”
Psychedelics as Transformative Therapeutics
Roth, B. L., & Gumpper, R. H. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230172 · Cited by 58
From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS)
Zeifman, R. J., Spriggs, M. J., Kettner, H., Lyons, T., Rosas, F. E., Mediano, P. A. M., Erritzøe, D., & Carhart-Harris, R. L. (2025) · Scientific Reports · doi:10.1038/s41598-023-28111-3 · Cited by 69
Self-citationEvens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
“Study selection The process for selecting studies included the following steps: (1) combination of search results from the two databases, (2) removal of duplicates, (3) screening of titles and abstracts, and (4) assessment of full-text articles to check for study eligibility.”
BackgroundMethodYaden, D. B., Berghella, A. P., Regier, P. S., Garcia‐Romeu, A., Johnson, M. W., & Hendricks, P. S. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103380 · Cited by 58
Understanding brain states across spacetime informed by whole-brain modelling
Vohryzek, J., Cabral, J., Vuust, P., Deco, G., & Kringelbach, M. L. (2022) · Philosophical Transactions of the Royal Society A Mathematical Physical and Engineering Sciences · doi:10.1098/rsta.2021.0247 · Cited by 67
“To this date, studies have investigated brain activity under the influence of psilocybin—in both healthy [75] and depressed populations [76,77], LSD [78], ayahuasca [79] and DMT [80].”
BackgroundMechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics
Jaster, A. M., & González‐Maeso, J. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02274-x · Cited by 61
“Further research from this group has compared the effects of psilocybin with a commonly prescribed antidepressant, escitalopram, in a double-blind randomized control trial [199].”
Tolerance and Cross-Tolerance among Psychedelic and Nonpsychedelic 5-HT2A Receptor Agonists in Mice
Revenga, M. D. L. F., Jaster, A. M., McGinn, J., Silva, G. M., Saha, S., & González‐Maeso, J. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00170 · Cited by 56
d’Andrea, G., Pettorruso, M., Lorenzo, G. D., Rhee, T. G., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., Nicola, M. D., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.038 · Cited by 60
Development and psychometric validation of a novel scale for measuring ‘psychedelic preparedness’
McAlpine, R. G., Blackburne, G., & Kamboj, S. K. (2024) · Scientific Reports · doi:10.1038/s41598-024-53829-z · Cited by 59
Psychedelic-assisted psychotherapy: Where is the psychotherapy research
Aday, J. S., Horton, D., Fernandes-Osterhold, G., O’Donovan, A., Bradley, E. R., Rosen, R. C., & Woolley, J. D. (2024) · Psychopharmacology · doi:10.1007/s00213-024-06620-x · Cited by 54
Belouin, S. J., Averill, L. A., Henningfield, J. E., Xenakis, S. N., Donato, I., Grob, C. S., Berger, A., Magar, V., Danforth, A. L., & Anderson, B. T. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109214 · Cited by 59
Caution at psychiatry’s psychedelic frontier
Burke, M. J., & Blumberger, D. M. (2021) · Nature Medicine · doi:10.1038/s41591-021-01524-1 · Cited by 57
The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology
Mastinu, A., Anyanwu, M., Carone, M., Abate, G., Bonini, S. A., Peron, G., Tirelli, E., Pucci, M., Ribaudo, G., Oselladore, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021329 · Cited by 57
Psychedelics in the treatment of eating disorders: Rationale and potential mechanisms
Calder, A. E., Mock, S., Friedli, N., Pasi, P., & Hasler, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.05.008 · Cited by 55
Wells, A., Fernandes, M. T. C. F., & Reynolds, L. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00294 · Cited by 56
Falchi-Carvalho, M., Palhano-Fontes, F., Wießner, I., Barros, H., Bolcont, R., Laborde, S., Silva, S. R. B., Montanini, D., Barbosa, D. C., Teixeira, E., et al. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02091-6 · Cited by 59
New and emerging treatments for major depressive disorder
Njenga, C., Ramanuj, P., de Magalhães, F. J. C., & Pincus, H. A. (2024) · BMJ · doi:10.1136/bmj-2022-073823 · Cited by 59
“26 In a subsequent phase 2 trial with 233 participants with treatment-resistant depression, a significant antidepressant effect was noted at the primary endpoint three weeks after a single dose of 25 mg of psilocybin with psychological support, but not for 10 mg, when compared with 1 mg of…”
BackgroundHusain, M. I., Ledwos, N., Fellows, E., Baer, J., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Castle, D. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1076459 · Cited by 50
Group psychedelic therapy: empirical estimates of cost-savings and improved access
Marseille, E. A., Stauffer, C. S., Agrawal, M., Thambi, P. M., Roddy, K., Mithoefer, M. C., Bertozzi, S., & Kahn, J. G. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1293243 · Cited by 57
Hodge, A. T., Sukpraprut‐Braaten, S., Narlesky, M. R., & Strayhan, R. C. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2044096 · Cited by 51
“A double-blind, randomized, controlled trial was conducted to assess the efficacy of psilocybin in treating moderate-to-severe major depressive disorder by comparing QIDS scores before and after treatment (Carhart-Harris et al. 2021).”
MethodInfluentialRosa, W. E., Sager, Z. S., Miller, M. E., Bernstein, I., Rinaldi, A. D., Addicott, K., Ljuslin, M., Adrian, C., Back, A. L., Beachy, J., et al. (2022) · Journal of Palliative Medicine · doi:10.1089/jpm.2022.0036 · Cited by 54
“47,48 Individuals with cancer metastatic to the brain or primary brain disease, 49 as well as patients with a personal or family history (first degree relative) of psychotic disorders or bipolar illness, were also excluded from participation.”
Psychotherapy with Psilocybin for Depression: Systematic Review
Dawood-Hristova, J. J., & Pérez‐Jover, V. (2023) · Behavioral Sciences · doi:10.3390/bs13040297 · Cited by 56
Brennan, B., Kelman, A. R., & Belser, A. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0007 · Cited by 52
Ethnoracial inclusion in clinical trials of psychedelics: a systematic review
Hughes, M. E., & Garcia‐Romeu, A. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102711 · Cited by 52
Psilocybin Facilitates Fear Extinction: Importance of Dose, Context, and Serotonin Receptors
Woodburn, S. C., Levitt, C. M., Koester, A., & Kwan, A. C. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00279 · Cited by 58
Prefrontal contributions to the stability and variability of thought and conscious experience
Zamani, A., Carhart-Harris, R. L., & Christoff, K. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-01147-7 · Cited by 51
Self-citationAnalysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review
Ziff, S., Stern, B., Lewis, G., Majeed, M., & Gorantla, V. R. (2022) · Cureus · doi:10.7759/cureus.21944 · Cited by 62
“GRID-HAMD: GRID-Hamilton Depression Rating Scale; QIDS-SR-16: Quick Inventory of Depressive Symptomatology–Self-Report; BDI: Beck Depression Inventory 1A”
BackgroundMethodResultInfluentialHusain, M. I., Blumberger, D. M., Castle, D. J., Ledwos, N., Fellows, E., Jones, B. D. M., Ortiz, A., Kloiber, S. M., Wang, W., Rosenblat, J. D., et al. (2023) · BJPsych Open · doi:10.1192/bjo.2023.535 · Cited by 57
Honk, L., Stenfors, C. U. D., Goldberg, S. B., Hendricks, P. S., Osika, W., Dourron, H. M., Lebedev, A. V., Petrović, P., & Simonsson, O. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.197 · Cited by 48
“Over the last twenty years, there has been a resurgence of clinical research on psychedelic therapy (Nutt & Carhart-Harris, 2021) and a growing body of research is now highlighting its possible efficacy in treating a broad range of mental health conditions, such as end-of-life anxiety (Griffiths et…”
BackgroundEffects of DMT on mental health outcomes in healthy volunteers
Timmermann, C., Zeifman, R. J., Erritzøe, D., Nutt, D. J., & Carhart-Harris, R. L. (2024) · Scientific Reports · doi:10.1038/s41598-024-53363-y · Cited by 55
“…trials involving psychedelics, and they have consistently been found to be reduced after psychedelic therapy in psychiatric patient populations 6–8, 10, 11, Tempering enthusiasm, we failed to replicate decreases in Neuroticism in the prospective sample, and we did not find increases in…”
BackgroundSelf-citationBornemann, J., Close, J. B., Spriggs, M. J., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.735427 · Cited by 53
“Consistent with literature (47), they particularly reported antidepressant and anxiolytic effects.”
BackgroundSelf-citationJones, G. M., & Nock, M. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-18645-3 · Cited by 52
Weiss, B., Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L., & Erritzoe, D. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.749788 · Cited by 47
Self-citationAre psychedelics the answer to chronic pain: A review of current literature
Kooijman, N. I., Willegers, T., Reuser, A. M., Mulleners, W. M., Kramers, C., Vissers, K. C. P., & van der Wal, S. E. I. (2023) · Pain Practice · doi:10.1111/papr.13203 · Cited by 53
“48 Interestingly, a recently published RCT by Carhart et al.(49) showed no significant difference between psilocybin and escitalopram in antidepressant effects.”
BackgroundEffect of lysergic acid diethylamide (LSD) on reinforcement learning in humans
Kanen, J. W., Luo, Q., Kandroodi, M. R., Cardinal, R. N., Robbins, T. W., Nutt, D. J., Carhart-Harris, R. L., & den Ouden, H. E. M. (2022) · Psychological Medicine · doi:10.1017/s0033291722002963 · Cited by 50
Self-citationEvaluating the Potential Use of Serotonergic Psychedelics in Autism Spectrum Disorder
Markopoulos, A., Inserra, A., De Gregorio, D., & Gobbi, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.749068 · Cited by 46
Kisely, S., Connor, M., Somogyi, A. A., & Siskind, D. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674221083868 · Cited by 38
“In addition, the field is rapidly evolving with the availability of more studies and data that were not included in previous reviews (Carhart-Harris et al., 2021; Davis et al., 2021; Mitchell et al., 2021; Wolfson et al., 2020).”
BackgroundResultPsiuk, D., Nowak, E., Dycha, N., Łopuszańska, U., Kurzepa, J., & Samardakiewicz, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911450 · Cited by 54
“2021 [43] 30 (6-week trial period), 30 (dosing-day 1) 25 mg feeling jittery: 7 (6-week trial), 0 (dosing-day 1) headaches: 67 (6-week trial), 43 (dosing-day 1); migraine: 10 (6-week trial), 0 (dosing-day 1); dizziness: 7 (6-week trial) nausea: 27 (6-week trial), 13 (dosing-day 1); vomiting: 7 (6-week trial), 0 (dosing…”
BackgroundResultInfluentialDifferent hierarchical reconfigurations in the brain by psilocybin and escitalopram for depression
Deco, G., Perl, Y. S., Johnson, S., Bourke, N., Carhart-Harris, R. L., & Kringelbach, M. L. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00298-y · Cited by 99
“We used a 32-channel head coil to acquire 480 volumes in ~10 min: 3-mm isotropic voxels; 44 axial slices; TE, 30 ms; TR, 1,250 ms; GRAPPA acceleration, 2; flip angle, 70°; bandwidth, 2,232 Hz per pixel.”
InfluentialSelf-citationThe costs and benefits of psychedelics on cognition and mood
Sayalı, C., & Barrett, F. S. (2023) · Neuron · doi:10.1016/j.neuron.2022.12.031 · Cited by 48
The structural diversity of psychedelic drug actions revealed
Gumpper, R. H., Jain, M. K., Kim, K., Sun, R., Sun, N., Xu, Z., DiBerto, J. F., Krumm, B. E., Kapolka, N. J., Kanıskan, H. Ü., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57956-7 · Cited by 46
Jaster, A. M., Elder, H., Marsh, S. A., Revenga, M. D. L. F., Negus, S. S., & González‐Maeso, J. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06092-x · Cited by 51
Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report
Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G. K., Ching, T. H. W., Belser, A., & Pittenger, C. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e12135 · Cited by 45
“findings of sustained improvement after one or two doses of psilocybin in major depressive disorder (Carhart-Harris et al., 2016; Carhart-Harris et al., 2021; Davis et al., 2021) and in depression and anxiety symptoms in individuals with late-stage cancer (Grob et al.”
BackgroundThe need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 43
Metadata
- Authors
- Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- From the Centre for Psychedelic Research, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-15
- Volume
- 384
- Issue
- 15
- Pages
- 1402-1411
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3156937150
- Cited by
- 1,391
- References
- 26
- Citations by year
- 2026: 200 · 2025: 278 · 2024: 287 · 2023: 284 · 2022: 247 · 2021: 92
- FWCI
- 154.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Alex Mosley Charitable Trust (NA)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- psilocybin, escitalopram, major depressive disorder, antidepressant efficacy, psychedelic therapy, selective serotonin reuptake inhibitors, depression remission, treatment-resistant depression, psychological support, hallucinations, dissociation, synesthesia, anxiety disorders
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Double-Blind Method, Female, Hallucinogens, Humans, Male, Middle Aged, Psilocybin, Surveys and Questionnaires, Citalopram, Antidepressive Agents, Second-Generation, Young Adult, Self Report
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.